CO6630142A2 - Compuestos de hidroxama de indolilo o indolinilo - Google Patents

Compuestos de hidroxama de indolilo o indolinilo

Info

Publication number
CO6630142A2
CO6630142A2 CO12184615A CO12184615A CO6630142A2 CO 6630142 A2 CO6630142 A2 CO 6630142A2 CO 12184615 A CO12184615 A CO 12184615A CO 12184615 A CO12184615 A CO 12184615A CO 6630142 A2 CO6630142 A2 CO 6630142A2
Authority
CO
Colombia
Prior art keywords
compounds
indolyl
indolinyl
hydroxama
treating cancer
Prior art date
Application number
CO12184615A
Other languages
English (en)
Inventor
Ching Shih Chen
Jing Ping Liou
Hsing Jin Liu
Kuo Sheng Hung
Pei Wen Shan
Wen Ta Chiu
Che Ming Teng
Original Assignee
Taipei Mediacl University
Univ Ohio State
Univ Nat Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taipei Mediacl University, Univ Ohio State, Univ Nat Taiwan filed Critical Taipei Mediacl University
Publication of CO6630142A2 publication Critical patent/CO6630142A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Compuestos indolilo o indolinilo. También se describe un método para tratar cáncer con estos compuestos.
CO12184615A 2010-03-29 2012-10-18 Compuestos de hidroxama de indolilo o indolinilo CO6630142A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31871510P 2010-03-29 2010-03-29

Publications (1)

Publication Number Publication Date
CO6630142A2 true CO6630142A2 (es) 2013-03-01

Family

ID=44710365

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12184615A CO6630142A2 (es) 2010-03-29 2012-10-18 Compuestos de hidroxama de indolilo o indolinilo

Country Status (19)

Country Link
US (2) US8846748B2 (es)
EP (1) EP2552887B1 (es)
JP (1) JP5868386B2 (es)
KR (1) KR101854610B1 (es)
CN (1) CN102947268B (es)
AU (1) AU2011238628B2 (es)
BR (1) BR112012024822B8 (es)
CA (1) CA2795085C (es)
CO (1) CO6630142A2 (es)
ES (1) ES2707234T3 (es)
IL (1) IL222170A (es)
MX (1) MX336994B (es)
MY (1) MY172081A (es)
NZ (1) NZ602696A (es)
PL (1) PL2552887T3 (es)
RU (1) RU2584682C2 (es)
SG (1) SG184294A1 (es)
TW (1) TWI429628B (es)
WO (1) WO2011126821A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6180417B2 (ja) * 2011-09-15 2017-08-16 タイペイ メディカル ユニバーシティ 心不全またはニューロン損傷の治療剤製造のための化合物の使用
EP2844259A4 (en) 2012-04-30 2015-11-11 Anderson Gaweco MMR MODULATORS AND USES THEREOF
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
EP3096753A4 (en) * 2013-11-24 2017-07-05 Taipei Medical University Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits
US10246455B2 (en) 2014-04-11 2019-04-02 Taipei Medical University Histone deacetylase inhibitors
US20150368195A1 (en) * 2014-06-20 2015-12-24 Taipei Medical University Indoline compounds for treatment and/or prevention of inflammation diseases
WO2016053947A1 (en) 2014-09-29 2016-04-07 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
MA41677A (fr) 2015-03-13 2021-06-02 Forma Therapeutics Inc Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
CN105085368B (zh) * 2015-04-23 2017-10-20 华侨大学 一种海参生物碱及其制备方法和应用
US10273246B2 (en) * 2015-05-18 2019-04-30 University Of Utah Research Foundation Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions
JP7302120B2 (ja) * 2015-10-27 2023-07-04 タイペイ メディカル ユニバーシティ 線維症疾患の治療及び／又は予防用インドリン誘導体
CN105348169B (zh) * 2015-11-16 2018-03-30 青岛大学 一种组蛋白去乙酰酶抑制剂(e)‑3‑(2‑(1‑(4‑氯苯甲酰基)‑5‑甲氧基‑2‑甲基‑1氢‑吲哚‑3‑基)乙酰氨基)‑n‑羟基丁‑2‑烯酰胺及其制备方法和应用
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
US11492341B2 (en) 2018-11-16 2022-11-08 Nimbus Artemis, Inc. ACLY inhibitors and uses thereof
CN111610260A (zh) * 2020-04-30 2020-09-01 广州汇标检测技术中心 一种兽药喹烯酮中乙酰甲喹的检测方法
CN112321479B (zh) * 2020-11-04 2022-02-08 吉林大学 一种桑寄生中具有抑菌活性的吲哚-4-甲醛化合物、制备方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0578315A (ja) * 1991-03-11 1993-03-30 Kyowa Hakko Kogyo Co Ltd インドール誘導体
EP0511477B1 (en) * 1991-03-11 1996-07-10 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives
WO1995014003A1 (fr) * 1993-11-17 1995-05-26 Kyowa Hakko Kogyo Co., Ltd. Derive de propenone
CA2203659A1 (en) * 1994-10-27 1996-05-09 Teruo Oku Pyridopyrimidones, quinolines and fused n-heterocycles as bradykinin antagonists
US7569724B2 (en) * 2000-09-29 2009-08-04 Topotarget Uk Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
US20020103192A1 (en) * 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
EE200300478A (et) * 2001-03-29 2003-12-15 Bristol-Myers Squibb Company Tsüklopropüülindooli derivaadid kui selektiivsed serotoniini tagasihaarde inhibiitorid
JP2004536071A (ja) 2001-05-25 2004-12-02 クイーンズ　ユニバーシティ　アット　キングストン 複素環ベータアミノ酸およびそれらの抗癲癇誘発剤としての使用
DE60333014D1 (de) * 2002-07-29 2010-07-29 Mitsubishi Paper Mills Ltd Organischer farbstoff, photoelektrisch signalgebendes material, halbleiterelektrode sowie photoelektrischer signalgeber
EP1735319B1 (en) 2004-03-26 2017-05-03 MethylGene Inc. Inhibitors of histone deacetylase
JP2006169189A (ja) 2004-12-17 2006-06-29 Rengo Co Ltd チョークブルード病抑止剤
WO2006101456A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
TW200718691A (en) * 2005-06-10 2007-05-16 Sigma Tau Ind Farmaceuti Cinnamic and phenylpropiolic acid derivatives useful as anti-tumour agents
TW200716545A (en) * 2005-06-10 2007-05-01 Sigma Tau Ind Farmaceuti Indole derivatives having anti-tumor activity
JP2009501236A (ja) * 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20080234349A1 (en) 2005-09-07 2008-09-25 Jack Lin PPAR active compounds
WO2007100066A1 (ja) * 2006-03-02 2007-09-07 Astellas Pharma Inc. １７βＨＳＤｔｙｐｅ５阻害剤
WO2007109178A2 (en) 2006-03-16 2007-09-27 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase
WO2008060721A1 (en) * 2006-11-14 2008-05-22 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of t-cell proliferative disorders
EP2123637A4 (en) 2006-11-30 2011-12-21 Tokyo Inst Tech NEW CURCUMINE DERIVATIVE
EA200901042A1 (ru) 2007-02-06 2010-02-26 Новартис Аг Производные 1-бензенсульфонил-1h-индола в качестве ингибиторов активности ccr9
RU2009139931A (ru) * 2007-03-29 2011-05-10 Асубио Фарма Ко., Лтд. (Jp) Производные индола, обладающие ингибирующей активностью в отношении сpla2, и способы их получения
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
EP2265590B8 (en) * 2008-04-15 2016-07-27 Pharmacyclics LLC Selective inhibitors of histone deacetylase

Also Published As

Publication number Publication date
AU2011238628B2 (en) 2016-10-27
IL222170A0 (en) 2012-12-02
EP2552887A4 (en) 2013-09-04
BR112012024822B1 (pt) 2021-09-08
WO2011126821A2 (en) 2011-10-13
CA2795085C (en) 2019-06-11
CA2795085A1 (en) 2011-10-13
US20140364477A1 (en) 2014-12-11
US9598364B2 (en) 2017-03-21
JP2013523747A (ja) 2013-06-17
JP5868386B2 (ja) 2016-02-24
WO2011126821A3 (en) 2012-04-19
TWI429628B (zh) 2014-03-11
IL222170A (en) 2015-05-31
US8846748B2 (en) 2014-09-30
RU2584682C2 (ru) 2016-05-20
EP2552887B1 (en) 2018-10-24
MX2012011337A (es) 2013-02-26
NZ602696A (en) 2015-03-27
US20110245315A1 (en) 2011-10-06
MY172081A (en) 2019-11-13
MX336994B (es) 2016-02-09
AU2011238628A1 (en) 2012-11-01
ES2707234T3 (es) 2019-04-03
BR112012024822A2 (pt) 2017-08-08
KR20130079372A (ko) 2013-07-10
BR112012024822B8 (pt) 2021-10-05
SG184294A1 (en) 2012-11-29
PL2552887T3 (pl) 2019-05-31
KR101854610B1 (ko) 2018-05-04
EP2552887A2 (en) 2013-02-06
TW201206883A (en) 2012-02-16
CN102947268A (zh) 2013-02-27
CN102947268B (zh) 2017-02-15
RU2012141499A (ru) 2014-05-10

Similar Documents

Publication Publication Date Title
CO6630142A2 (es) Compuestos de hidroxama de indolilo o indolinilo
CR20150507A (es) Inhibidores de histona desmetilasas
UA110338C2 (en) Chemical compounds
CR20140024A (es) Compuestos inhibidores de metaloenzimas
BR112013029787A2 (pt) biomarcadores para câncer de pulmão
UY34177A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
ECSP12012140A (es) Compuestos de para la inhibición de inmunoproteasomas
BR112013024211A2 (pt) tratamento de tumores sólidos
BR112013025755A2 (pt) aparelho de guincho
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
BR112016007891A2 (pt) uso de inibidores de bromodomínio cbp/ep300 para imunoterapia do câncer
EA201200999A1 (ru) Способы лечения рака молочной железы
CR20130539A (es) Triazolopiridinas
BR112013027726A2 (pt) instalação de poço submarino e método associado
CR20120637A (es) Triazolopiridinas sustituidas
UY34466A (es) Proceso para estabilizar contenido bacteriano de treparaciones minerales acuosas que comprenden carbbonatos de calcio.
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
CY1119492T1 (el) Παραγωγα καρβαμικα/ουριας
BR112017013093A2 (pt) processos para a preparação de um composto de diariltio-hidantoína
BR112013029484A2 (pt) método para o tratamento de tumores sólidos avançados
CL2015000192A1 (es) Método de seleccion de un sujeto que padece un tumor maligno para tratamiento con inhibidor de jak/stat que comprende determinar nivel de expresión de biomarcadores.
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
UY34465A (es) ?inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares?.
CL2011002403S1 (es) Luminaria solar.

Legal Events

Date Code Title Description
FC Application refused